Global Acute Kidney Injury Treatment & Management Market Growth (Status and Outlook) 2023-2029
KI happens in people who are already sick and in the hospital. People who are in the intensive care unit (ICU) are even more likely than people who are in other units of the hospital to have AKI. This is because people who need to be in the ICU are already very sick.
LPI (LP Information)' newest research report, the “Acute Kidney Injury Treatment & Management Industry Forecast” looks at past sales and reviews total world Acute Kidney Injury Treatment & Management sales in 2022, providing a comprehensive analysis by region and market sector of projected Acute Kidney Injury Treatment & Management sales for 2023 through 2029. With Acute Kidney Injury Treatment & Management sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Acute Kidney Injury Treatment & Management industry.
This Insight Report provides a comprehensive analysis of the global Acute Kidney Injury Treatment & Management landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Acute Kidney Injury Treatment & Management portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Acute Kidney Injury Treatment & Management market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Acute Kidney Injury Treatment & Management and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Acute Kidney Injury Treatment & Management.
The global Acute Kidney Injury Treatment & Management market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Acute Kidney Injury Treatment & Management is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Acute Kidney Injury Treatment & Management is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Acute Kidney Injury Treatment & Management is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Acute Kidney Injury Treatment & Management players cover B. Braun Melsungen AG, Baxter International, Inc., Asahi Kasei Medical Co., Ltd, Angion Biomedica Corp, AM-Pharma, Quark Pharmaceuticals, Inc and Fresenius Medical Care AG & Co. KGaA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Acute Kidney Injury Treatment & Management market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Prerenal Acute Kidney Injury
Intrinsic Renal Acute Kidney Injury
Postrenal Acute Kidney Injury
Segmentation by application
Hospitals
Ambulatory Surgical Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
B. Braun Melsungen AG
Baxter International, Inc.
Asahi Kasei Medical Co., Ltd
Angion Biomedica Corp
AM-Pharma
Quark Pharmaceuticals, Inc
Fresenius Medical Care AG & Co. KGaA
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook